Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118515 · ClinicalTrials.gov registry record · Phase 1
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
A Phase 1 study of Congenital Cytomegalovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 10
- Study locations
NCT06118515: Recruiting Phase 1 study of Congenital Cytomegalovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06118515 is a Phase 1 study of Congenital Cytomegalovirus Infection that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06118515, a Phase 1 study of Congenital Cytomegalovirus Infection, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immediately to the University of Alabama at Birmingham (UAB) Pharmacokinetic Lab and processed in real time. Within = 7 days, pharmacokinetics (PK) results will be conveyed to the study site. If the Area Under the Curve (AUC24) is =100,000 ngxhr/mL (see footnote a in Table 1), the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on Dose Finding Day. This duration of letermovir therapy was selected based upon our earlier observation in this population that patients with symptomatic congenital Cytomegalovirus (CMV) disease who achieve viral suppression to =2.5 log by day 14 of valganciclovir therapy and then maintain it over the next 4 months are statistically more likely to have improved hearing across the first two years of life (22). If the observed letermovir exposure of the subject is \> 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments. Oral valganciclovir (16 mg/kg/dose BID) will begin within the first month of life, as standard of care; initiation of valganciclovir can be concomitant with or prior to initiation of the 14-day course of letermovir (but will not start before obtaining the pharmacokinetics (PK) specimens following the single dose of letermovir on the Dose Finding Day). This is similar to the intensification approach that has been evaluated in the management of patients infected with human immunodeficiency virus (23-25). The day that the 14-day course o
Primary Outcome
Determined using the linear-log trapezoidal rule. In addition, a population PK analysis may be conducted at the end of the study.
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (10)
Alabama
- Children's of Alabama Child Health Research Unit (CHRU) - Birmingham
District of Columbia
- Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Kentucky
- University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases - Louisville
Louisiana
- Louisiana State University Health Shreveport - Infectious Diseases - Shreveport
Minnesota
- University of Minnesota - Pediatric Infectious Disease - Minneapolis
New York
- SUNY Upstate Medical University Hospital - Pediatrics - Syracuse
Ohio
- Nationwide Children's Hosp.-Neonatology-Ctr. for Perinatal Rsrch. - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
What NCT06118515 shows while recruiting
NCT06118515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Congenital Cytomegalovirus Infection appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06118515 lists 10 locations in 10 states (Alabama, District of Columbia, Georgia).
Frequently Asked Questions
What is clinical trial NCT06118515 about?
NCT06118515 is a clinical study titled "A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus". This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects wil...
What is the current status of trial NCT06118515?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-02-19. Estimated completion is 2026-08-31.
What conditions does trial NCT06118515 study?
This clinical trial studies the following conditions: Congenital Cytomegalovirus Infection.
What interventions are being tested in trial NCT06118515?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06118515?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118515 being conducted?
This trial has 10 study locations across Alabama, District of Columbia, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06118515's enrollment target sits among peer trials
12 1853rd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI